caa a22 4500 469049332 CHVBK 20180323132826.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF02921339 doi (NATIONALLICENCE)springer-10.1007/BF02921339 Antiserum directed against chromogranin A and B (CAB) is a useful marker for peptide hormone-producing endocrine cells and tumors [Elektronische Daten] [L. Larsson, J. Alumets, B. Eriksson, R. Håkanson, G. Lundquist, K. Öberg, F. Sundler] Certain proteins, such as the chromogranins, have a ubiquitous occurrence in nearly ail peptide hormone-producing cells. To date, little is known about their functional role as structural proteins, precursors of bioactive peptides, or enzymes. Such proteins may serve as markers for endocrine cells and tumors. In the present study, we have used an antiserum that recognizes both chromogranin A and B (CAB) to demonstrate peptide hormone-producing endocrine cells and tumors in humans. The antiserum demonstrated endocrine cells all along the gastrointestinal tract, most of the islet cells, the adrenomedullary cells, the thyroid C cells, scattered endocrine cells in the respiratory tract, and numerous cells in the adenohypophysis. The CAB-positive cells outnumbered those storing chromogranin A as studied in the intestines and the anterior pituitary. An array of different peptide hormone-producing tumor cells were also CAB-positive, including several types of islet cell tumors, gastric, intestinal, and bronchial carcinoids, medullary thyroid carcinomas, and pheochromocytomas. Thus, the CAB antiserum may help identify peptide hormone-producing cells and tumors. Humana Press Inc., 1992 Larsson L. Department of Medical Cell Research, University of Lund, Biskopsgatan 5, S-223 62, Lund, Sweden aut Alumets J. Department of Pathology, University of Lund, Sweden aut Eriksson B. Uppsala Branch, Ludwig Institute for Cancer Research Clinical Group, Sweden aut Håkanson R. Department of Pharmacology, University of Lund, Sweden aut Lundquist G. Department of Clinical Chemistry, University Hospital of Uppsala, Sweden aut Öberg K. Uppsala Branch, Ludwig Institute for Cancer Research Clinical Group, Sweden aut Sundler F. Department of Medical Cell Research, University of Lund, Biskopsgatan 5, S-223 62, Lund, Sweden aut Endocrine Pathology Humana Press 3/1(1992-03-01), 14-22 1046-3976 3:1<14 1992 3 12022 https://doi.org/10.1007/BF02921339 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02921339 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Larsson L. Department of Medical Cell Research, University of Lund, Biskopsgatan 5, S-223 62, Lund, Sweden aut NATIONALLICENCE 700 1- Alumets J. Department of Pathology, University of Lund, Sweden aut NATIONALLICENCE 700 1- Eriksson B. Uppsala Branch, Ludwig Institute for Cancer Research Clinical Group, Sweden aut NATIONALLICENCE 700 1- Håkanson R. Department of Pharmacology, University of Lund, Sweden aut NATIONALLICENCE 700 1- Lundquist G. Department of Clinical Chemistry, University Hospital of Uppsala, Sweden aut NATIONALLICENCE 700 1- Öberg K. Uppsala Branch, Ludwig Institute for Cancer Research Clinical Group, Sweden aut NATIONALLICENCE 700 1- Sundler F. Department of Medical Cell Research, University of Lund, Biskopsgatan 5, S-223 62, Lund, Sweden aut NATIONALLICENCE 773 0- Endocrine Pathology Humana Press 3/1(1992-03-01), 14-22 1046-3976 3:1<14 1992 3 12022 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer